SCHEDULE: Deep Track Capital Exits Dynavax Technologies Stake

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Dynavax Technologies Corporation, reducing their stake to 0%.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G for Dynavax Technologies Corporation.
• The filing indicates that the Reporting Persons no longer beneficially own any shares of Dynavax Technologies Corporation's Common Stock, with their aggregate ownership reduced to 0%.
• This amendment signifies a complete divestment of their previous holdings in the company.
• The beneficial ownership calculation is based on 117,424,968 shares of Dynavax Common Stock, as reported in the issuer's 10-Q filed on November 5, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development, as a complete divestment by a specialized institutional investor typically signals a lack of confidence in the company's future prospects.

Negatives

• Deep Track Capital and its affiliates have completely divested their beneficial ownership in Dynavax Technologies Corporation, reducing their stake to 0%.
• This divestment by a significant institutional investor could be perceived negatively by the market.

Risks

• The divestment by Deep Track Capital could signal a lack of confidence in Dynavax Technologies Corporation's future prospects by a sophisticated institutional investor.
• Such a move might lead to increased selling pressure on the stock if other investors interpret it as a negative indicator.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that a complete divestment by an institutional investor like Deep Track Capital, which specializes in biotechnology, can be a significant signal within the biotech sector. Such moves often prompt other investors to re-evaluate their positions, especially if the fund has a strong track record or specific insights into the industry.

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.
• Potential Investors: Prospective investors might view this divestment as a red flag, prompting further due diligence or deterring investment.

Key Dates

Recommendation

The complete divestment by Deep Track Capital, a specialized biotechnology investor, suggests a loss of confidence in Dynavax Technologies Corporation. This action by a sophisticated institutional player often precedes or accompanies further stock price declines, making a "sell" recommendation prudent for investors to mitigate potential losses.

Keywords

Dynavax Technologies, Deep Track Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Stock Divestment, Biotechnology, Investment Fund